BRIEF published on 12/11/2025 at 23:05, 1 month 20 days ago Xenetic Biosciences Adjourns 2025 Annual Stockholders Meeting Xenetic Biosciences Stockholders Meeting Voting Instructions Quorum 2025 Adjournment
PRESS RELEASE published on 12/11/2025 at 23:00, 1 month 20 days ago Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting Xenetic Biosciences, Inc. adjourns 2025 Annual Meeting of Stockholders due to lack of quorum. Stockholders urged to vote before reconvened meeting on January 8, 2026 Xenetic Biosciences Stockholders Quorum Proxy Vote 2025 Annual Meeting
BRIEF published on 11/19/2025 at 14:50, 2 months 11 days ago Xenetic Biosciences Extends Collaboration with Scripps Research Cancer Treatment Biopharmaceutical DNase I CAR-T Therapy Scripps Research
PRESS RELEASE published on 11/19/2025 at 14:45, 2 months 11 days ago Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform Xenetic Biosciences extends collaboration with Scripps Research to advance DNase-based immuno-oncology treatment for cancers Xenetic Biosciences Immuno-oncology DNase I CAR-T Therapy Scripps Research
BRIEF published on 11/13/2025 at 14:50, 2 months 17 days ago Xenetic Biosciences Reports Q3 2025 Financial Results Financial Results Revenue Increase Clinical Trials Pancreatic Carcinoma DNase Technology
PRESS RELEASE published on 11/13/2025 at 14:45, 2 months 17 days ago Xenetic Biosciences, Inc. Reports Third Quarter 2025 Financial Results Xenetic Biosciences, Inc. reports Q3 2025 financial results, focuses on DNase-based technology for cancer treatment. Secured $3.9 million from offering, advancing collaborations Xenetic Biosciences Cancer Treatment Collaborations DNase Technology Q3 2025 Financial Results
BRIEF published on 10/10/2025 at 15:35, 3 months 21 days ago Xenetic Biosciences Announces $4.5 Million Stock Offering Xenetic Biosciences Biopharmaceutical Immuno-oncology Stock Offering Canaccord Genuity
PRESS RELEASE published on 10/10/2025 at 15:30, 3 months 21 days ago Xenetic Biosciences, Inc. Announces Pricing of $4.5 Million Underwritten Offering of Common Stock Xenetic Biosciences, Inc. announces pricing of underwritten stock offering, aiming to raise $4.5 million for immuno-oncology technologies. Canaccord Genuity acts as bookrunner Xenetic Biosciences Stock Offering Immuno-oncology Technologies Canaccord Genuity S-3 Registration Statement
BRIEF published on 08/13/2025 at 14:05, 5 months 18 days ago Xenetic Biosciences Reports Q2 2025 Financial Results Financial Results Xenetic Biosciences Q2 2025 DNase I Development Partnership Expansions
PRESS RELEASE published on 08/13/2025 at 14:00, 5 months 18 days ago Xenetic Biosciences, Inc. Reports Second Quarter 2025 Financial Results Xenetic Biosciences, Inc. reports Q2 2025 results, expands partnership with The Scripps Research Institute for DNase I with CAR T-cell therapies and ends quarter with $4.8M cash Financial Results Xenetic Biosciences DNase I The Scripps Research Institute CAR T-cell Therapies
Published on 01/31/2026 at 03:15, 1 day 7 hours ago Empress Royalty Announces Grant Of Restricted Share Units
Published on 01/31/2026 at 01:40, 1 day 9 hours ago Star Copper Announces Grant of RSUs, Stock Options and PSUs
Published on 01/30/2026 at 23:00, 1 day 11 hours ago Avidian Gold Corp. Announces Director Resignation
Published on 01/31/2026 at 15:54, 18 hours 51 minutes ago EQS-Adhoc: Wolford AG: Capital increase will not be implemented
Published on 01/31/2026 at 12:25, 22 hours 20 minutes ago JOHNNIE WALKER TOASTS MUSIC'S BIGGEST WEEKEND WITH THE GO GO HIGHBALL
Published on 01/31/2026 at 02:45, 1 day 8 hours ago CANADA BACKS NEW DEFENCE, SECURITY AND RESILIENCE BANK
Published on 01/30/2026 at 22:00, 1 day 12 hours ago Nebius Group N.V. announces date of fourth quarter and full year 2025 results and conference call
Published on 01/30/2026 at 20:10, 1 day 14 hours ago Cynosure Lutronic Announces Completion of EU MDR Approval and Global Momentum for Mosaic 3D™ Ahead of IMCAS 2026
Published on 01/30/2026 at 17:45, 1 day 17 hours ago Schneider Electric launches a capital increase reserved for employees
Published on 01/29/2026 at 18:00, 2 days 16 hours ago GUILLEMOT CORPORATION: FULL-YEAR 2025 CONSOLIDATED TURNOVER UP 2%
Published on 01/29/2026 at 17:45, 2 days 17 hours ago LANSON-BCC ANNOUNCES 2025 REVENUES AND FINALISES THE ACQUISITION OF HEIDSIECK & C° MONOPOLE
Published on 01/29/2026 at 17:45, 2 days 17 hours ago Cegedim generated LFL revenue growth of 1.1% in 2025
